These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 8363442)

  • 41. A predictive model for the release of slightly water-soluble drugs from HPMC matrices.
    Fu XC; Wang GP; Wang YH; Liang WQ
    Pharmazie; 2004 Aug; 59(8):624-6. PubMed ID: 15378852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diffusion coefficients of polymer chains in the diffusion layer adjacent to a swollen hydrophilic matrix.
    Ju RT; Nixon PR; Patel MV
    J Pharm Sci; 1997 Nov; 86(11):1293-8. PubMed ID: 9383743
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Preparation of buspirone hydrochloride buccal adhesive tablet and study on its drug release mechanism].
    Du Q; Ping QN; Liu GJ
    Yao Xue Xue Bao; 2002 Aug; 37(8):653-6. PubMed ID: 12567784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modeling of drug release from erodible tablets.
    Katzhendler I; Hoffman A; Goldberger A; Friedman M
    J Pharm Sci; 1997 Jan; 86(1):110-5. PubMed ID: 9002469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Preparation and in vitro release of tetramethylpyrazine phosphate pulsincap capsule controlled by an erodible plug].
    Wu F; Zhang ZR; He WL; Zhang Y
    Yao Xue Xue Bao; 2002 Sep; 37(9):733-8. PubMed ID: 12567902
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Preparation of diltiazem hydrochloride delayed-onset, sustained release tablet].
    Zhang N; Zhu JB
    Yao Xue Xue Bao; 2002 Sep; 37(9):724-7. PubMed ID: 12567900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
    Koller WC; Block GA; Ahlskog JE; Ahrens S; Cedarbaum JM; Cyhan G; Goetz CG; LeWitt PA; Liss C; McLean L
    Clin Neuropharmacol; 1991 Aug; 14(4):322-9. PubMed ID: 1913699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG; Diederich NJ
    Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide).
    Ahlskog JE; Muenter MD; Bailey PA; Stevens PM
    Arch Neurol; 1992 May; 49(5):560-8. PubMed ID: 1580821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism.
    Cutler NR; Reines SA; McLean LF; Sramek JJ; Porras AG; Hand EL
    Clin Pharmacokinet; 1992 Mar; 22(3):223-30. PubMed ID: 1348452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Poor tolerability of MK-458.
    Cutler NR; Sramek JJ; Block GA
    Arch Neurol; 1993 Sep; 50(9):896. PubMed ID: 8363442
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.